felt Thanks
Learn about the DCM Foundation’s 3 Pillars: 1.) Information & Education 2.) Patient and Family Support 3.) Genetic Testing Awareness. Learn what this means for DCM patients and their family members.
Read More… from DCM Foundation’s Strategic Pillars Unveiled – What this Means for You
Renovacor Announces Partnerships with the Dilated Cardiomyopathy Foundation, the Heart Failure Society of America, and the American Association of Heart Failure Nurses to Help Increase Awareness of Genetic Heart Disorders PHILADELPHIA, PA, February 28, 2022 — Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients
Many of those diagnosed with heart failure don’t know that heredity may have contributed to their condition, a trait that they can pass on to their children as well. The disease, called dilated cardiomyopathy, often goes unnoticed and undiagnosed until it becomes life-threatening, but now a new study by researchers at The Ohio State University Wexner
Special guests Dr. Kathy Crispell and Dr. Ray Hershberger answer questions about heart failure resulting from dilated cardiomyopathy.
Join HFSA in promoting the 3rd annual Virtual Heart Failure Patient & Caregiver Day, taking place Saturday, February 12, 2022. #HFPatientDay2022 features interactive educational discussions with leading heart failure experts, a heart-healthy cooking demonstration, an exercise demonstration and more! To register for the event, please click HERE. Registration is complimentary to all heart failure patients, caregivers,
A 19-year-old mother from Allerton, England was diagnosed with dilated cardiomyopathy and fell very ill when she was pregnant, forcing an early birth via c-section. She received a heart transplant and initially faced complications that kept her in the hospital, but she eventually recovered. Her resolution now is to “live her best life”. Read her whole
Read More… from Woman Vows to “Live Her Best Life” After DCM & Heart Transplant
Tenaya Therapeutics, a biotechnology company committed to discovering, developing, and delivering curative therapies that address the underlying causes of heart disease, is sponsoring a study to better understand pediatric cardiomyopathy due to the MYBPC3 mutation. The MyClimb Natural History Study is designed to collect and evaluate information on the course of cardiomyopathy in children and adolescents <18
Read More… from Natural History Study Seeks Participants with MYBPC3 Genetic Mutation
Learn from 3 DCM patients about their experiences living with DCM: – Daily Activities – Staying Active – Managing Stress and Anxiety
By creating scientific forums to foster collaboration and creativity, Tenaya Therapeutics has been able to optimize gene therapy manufacturing. Such advancements can help make gene therapy more accessible and affordable for larger patient populations. Read the full article here: https://www.cellandgenecollaborative.com/doc/the-ties-that-bind-engineering-a-cgt-manufacturing-centric-culture-0001
The latest in DCM therapies in development – with Tenaya Therapeutics
Read More… from The Latest in DCM therapies in Development – with Tenaya
